Pneumococcal Disease

Vaxcyte Inc (NASDAQ: PCVX) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common...

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer Inc's (NYSE: PFE) Prevnar 20 pneumococcal vaccine for routine use. The CDC's Advisory Committee has also voted to recommend...

For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co Inc (NYSE: MRK). The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria. That’s two more...